Liminatus Pharma, Inc.

Snapshot

Liminatus is a pre-revenue biotech micro-cap in a severe financial crunch. With zero dollars of sales in the last three years and a net loss of $10.2M in FY 2025, the business is burning cash fast.

What's Happening Right Now

• Mon 13th Jul '26 · Corporate Action: The company proposed a reverse stock split of up to 1-for-50 to regain compliance with Nasdaq minimum bid price rules.
• Mon 6th Jul '26 · Acquisition: Liminatus completed its acquisition of InnocsAI, issuing 1.6 billion shares of common stock to acquire CAR-T therapy assets.
• Thu 4th Jun '26 · Financing: Liminatus raised $1.9 million by inducing warrant holders to exercise at a reduced price, issuing new warrants that require stockholder approval.
• Thu 21st May '26 · Regulatory: Nasdaq issued a delisting notice because the company failed to meet market value of listed securities requirements.
• Fri 15th May '26 · Financials: The company disclosed substantial doubt about its ability to continue as a going concern in its latest quarterly report due to cash constraints.